CN115103689A - 用于药物递送的树枝状大分子组合物和方法 - Google Patents

用于药物递送的树枝状大分子组合物和方法 Download PDF

Info

Publication number
CN115103689A
CN115103689A CN202080095453.0A CN202080095453A CN115103689A CN 115103689 A CN115103689 A CN 115103689A CN 202080095453 A CN202080095453 A CN 202080095453A CN 115103689 A CN115103689 A CN 115103689A
Authority
CN
China
Prior art keywords
composition
dendrimer
inhibitors
tumor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095453.0A
Other languages
English (en)
Chinese (zh)
Inventor
J.克莱兰德
R.夏尔马
M.孙
S.阿皮亚尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashwata Therapeutics Co ltd
Original Assignee
Ashwata Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashwata Therapeutics Co ltd filed Critical Ashwata Therapeutics Co ltd
Publication of CN115103689A publication Critical patent/CN115103689A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202080095453.0A 2019-12-04 2020-12-04 用于药物递送的树枝状大分子组合物和方法 Pending CN115103689A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962943705P 2019-12-04 2019-12-04
US62/943,705 2019-12-04
US202063108186P 2020-10-30 2020-10-30
US63/108,186 2020-10-30
PCT/US2020/063332 WO2021113651A2 (en) 2019-12-04 2020-12-04 Dendrimer compositions and methods for drug delivery

Publications (1)

Publication Number Publication Date
CN115103689A true CN115103689A (zh) 2022-09-23

Family

ID=74104190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095453.0A Pending CN115103689A (zh) 2019-12-04 2020-12-04 用于药物递送的树枝状大分子组合物和方法

Country Status (9)

Country Link
US (3) US20210170040A1 (https=)
EP (1) EP4069307A2 (https=)
JP (1) JP2023504286A (https=)
CN (1) CN115103689A (https=)
AU (1) AU2020397063A1 (https=)
CA (1) CA3163886A1 (https=)
IL (1) IL293604A (https=)
PH (1) PH12022551368A1 (https=)
WO (1) WO2021113651A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116196292A (zh) * 2023-02-16 2023-06-02 东华大学 一种靶向肽修饰的聚酰胺-胺树状大分子复合纳米材料及其制备方法
CN118108799A (zh) * 2024-04-29 2024-05-31 内蒙古工业大学 基于DMXAA的含Se多肽药物及其制备方法和应用
CN118846078A (zh) * 2024-07-02 2024-10-29 中国人民解放军空军军医大学 Ndrg2基因联合分子靶向抑制剂在制备肾细胞癌治疗药物中的应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
PH12022552818A1 (en) 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
US20230364244A1 (en) * 2020-07-17 2023-11-16 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to injured kidney
WO2022094327A1 (en) * 2020-10-30 2022-05-05 Ashvattha Therapeutics, Inc. Radiolabeled ether dendrimer conjugates for pet imaging and radiotherapy
US20240139107A1 (en) * 2021-03-08 2024-05-02 Transdermal Biotechnology, Inc. Dendrimer-n-acetyl-l-cysteine conjugates for treatment or prevention of aging skin or other indications
WO2022261504A1 (en) * 2021-06-10 2022-12-15 Ashvattha Therapeutics, Inc. Dendrimer conjugates and methods of use thereof
WO2023173124A1 (en) * 2022-03-10 2023-09-14 Cheng Kun Novel phosphoinositide 3-kinase (pi3k) inhibitor, compositions comprising the same, methods of making, and methods of treating a disease
WO2023183367A1 (en) * 2022-03-22 2023-09-28 Board Of Regents Of The University Of Nebraska Metformin nanoformulations and methods of use thereof
CN114796492B (zh) * 2022-05-12 2023-01-13 大连理工大学 一种超声驱动纳米声敏疫苗及其制备和应用
WO2025183982A1 (en) * 2024-02-28 2025-09-04 Washington State University Psma-targeted dendrimer nanoplatform for cancer detection and therapy
WO2025226820A1 (en) * 2024-04-23 2025-10-30 Ashvattha Therapeutics, Inc. Csf1r inhibitor dendrimer conjugates and uses thereof
WO2025259214A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as anti-skinning agents
WO2025259215A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as complexing ligands for metal activity enhancement

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
US20140371401A1 (en) * 2013-06-17 2014-12-18 Universidad De Talca Pamam, spacer molecule and cafestol polymers
WO2015168347A1 (en) * 2014-04-30 2015-11-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
WO2016025745A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders
WO2016025741A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Selective dendrimer delivery to brain tumors
US20170119897A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
US20190142964A1 (en) * 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856807A (en) 1972-03-13 1974-12-24 Upjohn Co L-({60 s,5s)-{60 -amino-3-chloro-2-isoxazoline-5-acetic acid
US3878047A (en) 1973-02-02 1975-04-15 Upjohn Co Process for production of AT-125
US5087639A (en) 1988-11-02 1992-02-11 The Upjohn Company Preventing CNS toxicity of acivicin when used with four large neutral amino acids
CA2940803A1 (en) * 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
CA2767163A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
EP2552458A4 (en) 2010-03-31 2014-08-27 Univ Wayne State INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES
EA036983B1 (ru) * 2014-05-21 2021-01-22 АйСиДи-ТЕРАПЬЮТИКС ГМБХ Терапевтические конъюгаты с сульфатированными дендримерами для внутриклеточного нацеливания
JP6847848B2 (ja) * 2014-12-15 2021-03-24 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤、及び緑内障の治療におけるその使用方法
KR101918346B1 (ko) * 2015-05-06 2018-11-13 경북대학교 산학협력단 난용성 활성물질의 수용성 덴드리머 복합체
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
WO2019071153A1 (en) * 2017-10-05 2019-04-11 Sony Corporation PROGRAMMABLE DENDRITIC MEDICINES
US20210330600A1 (en) * 2018-12-21 2021-10-28 Tiba Biotech Llc Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
JP7759322B2 (ja) * 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
US20140371401A1 (en) * 2013-06-17 2014-12-18 Universidad De Talca Pamam, spacer molecule and cafestol polymers
WO2015168347A1 (en) * 2014-04-30 2015-11-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
WO2016025745A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders
WO2016025741A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Selective dendrimer delivery to brain tumors
US20170119897A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
US20190142964A1 (en) * 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2019094952A1 (en) * 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUGO YAMASHITA等: "Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis", JOURNAL OF DRUG TARGETING, vol. 26, no. 9, pages 818 - 828 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116196292A (zh) * 2023-02-16 2023-06-02 东华大学 一种靶向肽修饰的聚酰胺-胺树状大分子复合纳米材料及其制备方法
CN118108799A (zh) * 2024-04-29 2024-05-31 内蒙古工业大学 基于DMXAA的含Se多肽药物及其制备方法和应用
CN118846078A (zh) * 2024-07-02 2024-10-29 中国人民解放军空军军医大学 Ndrg2基因联合分子靶向抑制剂在制备肾细胞癌治疗药物中的应用

Also Published As

Publication number Publication date
US20210170040A1 (en) 2021-06-10
US20230226199A1 (en) 2023-07-20
PH12022551368A1 (en) 2023-05-08
EP4069307A2 (en) 2022-10-12
CA3163886A1 (en) 2021-06-10
AU2020397063A1 (en) 2022-07-07
JP2023504286A (ja) 2023-02-02
US20230372499A1 (en) 2023-11-23
IL293604A (en) 2022-08-01
WO2021113651A3 (en) 2021-08-26
WO2021113651A2 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
CN115103689A (zh) 用于药物递送的树枝状大分子组合物和方法
TW202108179A (zh) 細胞毒性劑經由支鏈連接子與細胞結合分子的偶聯物
JP7719072B2 (ja) 三分岐ｎ－アセチルガラクトサミン修飾ヒドロキシルポリアミドアミンデンドリマーおよびその使用方法
CN119158034A (zh) 特异于结合素-4的双环肽配体
ES2863369T3 (es) Terapias inmunoablativas
WO2025247082A1 (en) An antibody-drug conjugate having two or more different functional small molecules for enhanced treatment of refractory diseases.
JP2021523151A (ja) 負の表面電荷を有するマイクロ粒子及びナノ粒子
US20250049963A1 (en) Glycosylated dendrimers for targeted intracellular delivery
US12303724B2 (en) Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer
WO2022187631A1 (en) Micelle releasing thermosensitive hydrogels as a therapeutic delivery system
KR20210024065A (ko) 아연 제제를 이용한 종양학 치료
US20240026294A1 (en) Nanoparticle-mediated immune cell manufacture and use thereof
HK40081468A (en) Dendrimer compositions and methods for drug delivery
US20230381349A1 (en) Methods and compositions for imaging and treating cancer
Zuo et al. H-ferritin engineered nanoplatform reprograms metabolism and immunity for glioblastoma immunotherapy
WO2026046110A1 (zh) 一种基于工程化红细胞的新型药物递送系统
TW202608449A (zh) 替拉紮明（ｔｉｒａｐａｚａｍｉｎｅ）組合物及方法
WO2024196783A1 (en) Bioengineered colon-specific immune niche for the treatment of ulcerative colitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081468

Country of ref document: HK